PMCPA Case Library

1,752 PMCPA Rulings.
Every One Analysed.

The only structured, searchable PMCPA case library in the UK. Expert video walkthroughs, podcast episodes, and MCQ assessments on every ruling — so you understand why companies breach the Code, not just that they did.

▶ Video analysis per case
🎧 Podcast per case
✍ MCQ + CPD certificate
🔒 From £299/year
1752+
Case Studies
5 min
Per Video
5 pts
Per Case Passed
8
Themes
📚
Subscribe for full case library access
Read free summaries below, or subscribe to unlock expert video walkthroughs, podcast audio and CPD certificates.
Sign in See plans ↓
Free — Browsing
✓ Browse all 1752+ case titles
✓ Filter by theme & therapy area
✓ See case reference, company & outcome
✗ Search by company or clause
✗ Video walkthroughs
✗ Podcast episodes
✗ MCQ assessments & CPD certificates
Subscribed — Full Access
✓ Search by company, clause & case ref
✓ Expert video walkthrough per case
✓ Podcast episode per case
✓ MCQ quiz — 5 CPD points per pass
✓ Personalised CPD completion certificate
✓ New cases added monthly
Subscribe from £299/year →
Search by company, clause, case reference... 🔒
All (1752) Social Media & Digital (720) HCP Hospitality & Meetings (431) Data & Publications (321) Off-label Promotion (219) Patient Organisations (44) Transfers of Value (9) Promotional Material (4) Samples & Gifts (2)
Therapy Area: All areas Other (360) Oncology (218) Cardiovascular (189) Respiratory (178) CNS & Neurology (169) Infectious Diseases (115) Diabetes (114) Rare Diseases (104) Immunology & Rheumatology (84) Dermatology (67) Obesity & Weight Management (63) Musculoskeletal & Bone (60) Ophthalmology (31)
Showing 15 results · Off-label Promotion · Obesity & Weight Management  · Clear
🔒 Subscribers only
AUTH/3445/12/20
Off-label Promotion Not Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Novo Nordisk Ozempic email alleged off-label promotion to under-18s (No breach)
A health professional complained about a Novo Nordisk promotional email for Ozempic (semaglutide) (ref UK20OZM00311) sent via Pulse.The email referenced SUSTAIN 7 data and included claims such as �…
Clauses: NONE
2020 🔒 Subscribe
🔒 Subscribers only
AUTH/3427/11/20
Off-label Promotion Not Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Novo Nordisk
Eli Lilly complained about two Novo Nordisk slide decks on cardiovascular outcome trials (CVOTs) in type 2 diabetes (refs UK19OZM00368 Nov 2019 and UK20DI00110 April 2020). The complaint focused on…
Clauses: NONE
2020 🔒 Subscribe
🔒 Subscribers only
AUTH/3245/9/19
Off-label Promotion Not Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Novo Nordisk
An anonymous, contactable individual describing themself as a GP (later noted to be assisted by an ex-employee during the appeal) complained about Novo Nordisk representatives’ promotion of Ozemp…
Clauses: NONE
2019 🔒 Subscribe
🔒 Subscribers only
AUTH/3258/10/19
Off-label Promotion Not Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Novo Nordisk breached ABPI Code over Ozempic formulary guide omitting retinopathy risk (AUTH/3258/10
A contactable complainant (later joined by an ex-employee) complained about the promotion of Ozempic (semaglutide) by Novo Nordisk.Allegations included: company staff helping to write local formula…
Clauses: NONE
2019 🔒 Subscribe
🔒 Subscribers only
AUTH/3057/8/18
Off-label Promotion Not Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Novo Nordisk
The head of prescribing and medicines management at a CCG complained about promotion of Victoza (liraglutide) by a named Novo Nordisk representative.Allegation: on 8 August 2018 the representative …
Clauses: NONE
2018 🔒 Subscribe
🔒 Subscribers only
AUTH/2638/9/13
Off-label Promotion Not Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Sanofi breached ABPI Code over Lyxumia cost comparison vs Bydureon in basal-insulin leavepiece (AUTH
Bristol-Myers Squibb and AstraZeneca complained about a Sanofi promotional leavepiece for Lyxumia (lixisenatide) (ref GBIE.LYX.13.04.14) focused on adding Lyxumia to basal insulin.The leavepiece in…
Clauses: NONE
2013 🔒 Subscribe
🔒 Subscribers only
AUTH/2600/4/13
Off-label Promotion Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Sanofi
Novo Nordisk complained about Sanofi promotional materials for Lyxumia (lixisenatide): a representatives’ leavepiece (ref GBIE.LYX.13.01.14 (PRO 20055)), a one-off mailer (ref GBIE.LYX.13.02.02 (…
2013 🔒 Subscribe
🔒 Subscribers only
AUTH/2604/5/13
Off-label Promotion Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Novo Nordisk v Sanofi
Novo Nordisk complained about a Sanofi advertisement for Lyxumia (lixisenatide) published in the Health Service Journal (March 2013) (ref GBIE.LYX.13.02.11).The ad included the claim: “Lyxumia is…
Clauses: 3.2,4.1
2013 🔒 Subscribe
🔒 Subscribers only
AUTH/2500/4/12
Off-label Promotion Not Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Eisai breached ABPI Code over Zonegran detail aid implying weight-loss benefit (AUTH/2500/4/12)
An anonymous consultant neurologist complained that an Eisai representative’s discussion and promotional materials for Zonegran (zonisamide) implied it could be used in overweight epileptic patie…
Clauses: NONE
2012 🔒 Subscribe
🔒 Subscribers only
AUTH/2569/12/12
Off-label Promotion Not Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Novo Nordisk detail aid for Victoza
Merck Sharp & Dohme (MSD) complained about a Novo Nordisk Victoza (liraglutide) detail aid titled “The value of Victoza” (ref UK/LR/0212/0048).The detail aid used a meta-analysis (Zinman et…
Clauses: NONE
2012 🔒 Subscribe
🔒 Subscribers only
AUTH/2157/8/08
Off-label Promotion Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Sanofi-Aventis — Acomplia (rimonabant)
A practice pharmacist complained about a four-page leavepiece, “Nice news for Norman”, promoting Acomplia (rimonabant), left by a Sanofi-Aventis representative.The complainant alleged the front…
Clauses: 7.2
2008 🔒 Subscribe
🔒 Subscribers only
AUTH/2164/9/08
Off-label Promotion Not Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Takeda
Merck Sharp & Dohme complained about a two-page journal advertisement (ref AB080313) for Actos (pioglitazone) and Competact (pioglitazone/metformin) issued by Takeda UK Limited, which appeared …
Clauses: NONE
2008 🔒 Subscribe
🔒 Subscribers only
AUTH/1844/6/06
Off-label Promotion Not Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Sanofi-Aventis breached the Code with unsolicited “horizon scanning” email about unlicensed rimonaba
The head of prescribing at a Primary Care Trust (PCT) received an email from Sanofi-Aventis (end of May 2006) about the licensing status of rimonabant and how to obtain further information.The emai…
Clauses: NONE
2006 🔒 Subscribe
🔒 Subscribers only
AUTH/1871/7/06
Off-label Promotion Not Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Sanofi-Aventis Acomplia (rimonabant) GP ad
A doctor complained about a Sanofi-Aventis advertisement for Acomplia (rimonabant) published in GP.The ad headline stated: “Cardiometabolic risk factors in overweight patients can be where you le…
Clauses: NONE
2006 🔒 Subscribe
🔒 Subscribers only
AUTH/1882/8/06
Off-label Promotion Upheld 🏥 Obesity & Weight Management ▶ Video 🎙 Podcast
Sanofi
A general practitioner complained about an Acomplia (rimonabant) page tag issued by Sanofi-Aventis and attached to a full-page MIMS advertisement for Acomplia.The tag featured only the brand name �…
Clauses: 9.1,18.3
2006 🔒 Subscribe
Unlock the Full Case Library
Annual subscription — instant access, cancel anytime.
🏆
The only PMCPA case library of its kind
No other provider publishes a structured, searchable library of PMCPA rulings with video and podcast. A single half-day compliance workshop from a specialist provider typically costs £499+ — for one session. Individual access here is £299 for a full year of 2,000+ cases.
PMCPA Case Library — Team (100 seats)
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
Enquire for bulk pricing →
Individual
For a single learner
£299
per year
Less than a single half-day workshop
  • 1 user seat
  • All 1752+ case studies
  • Video + podcast per case
  • MCQ quiz per case
  • 5 points per case passed
  • New cases added monthly
Create account or sign in to buy
Most Popular
Team 5
Up to 5 team members
£999
per year (£200/seat)
£200/person — the most cost-effective team option
  • 5 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • New cases added monthly
  • Admin management portal
Create account or sign in to buy
Team 25+
25+ team members
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
  • 25 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • Bulk seat management
  • Priority support
Enquire for bulk pricing →

Questions? Email [email protected]  ·  14-day money-back guarantee  ·  Annual subscription, auto-renews